Dalia Ercan
Moffitt Cancer Center(US)Cancer Clinic(US)Zhejiang University(CN)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, HER2/EGFR in Cancer Research, Cancer therapeutics and mechanisms, Fibroblast Growth Factor Research, Cytokine Signaling Pathways and Interactions
Most-Cited Works
- → Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M(2015)1,518 cited
- → Novel mutant-selective EGFR kinase inhibitors against EGFR T790M(2009)989 cited
- → Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies(2012)862 cited
- → Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors(2016)858 cited
- → Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab(2011)661 cited
- → Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer(2013)602 cited
- → A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors